Browse Companies

Foghorn Therapeutics continues advancing its proprietary chromatin-targeting platform with its lead clinical candidate FHD-909 in Phase 1 trials, supported by strategic collaboration with Eli Lilly. The company’s operating losses narrowed slightly in 2025 compared to 2024, reflecting a gradual ramp in partnered programs and platform development alongside non-cash asset impairments and lease restructuring costs. While no product sales revenues have yet emerged, deferred collaboration revenue provides some near-term financial cushioning, complemented by over $158 million in cash and securities as of the end of 2025. Despite improving operating cash flow trends, the company remains dependent on external capital markets for funding its pipeline expansion and commercialization readiness.

First Choice Healthcare Solutions, Inc. (FCHS) is executing a strategic transformation away from traditional orthopedic services toward operating a national medical functional health and wellness clinic network. The latest quarterly filing highlights ongoing divestiture of legacy lines and integration of acquisitions like Pointe Medical Services and The Good Clinic to scale Nurse Practitioner-driven personalized care and pharmacy offerings. Despite significant liquidity constraints and operating losses, FCHS’s business model focuses on scalable lower-cost provider staffing, a diversified cash-pay service mix, and cloud-based infrastructure benefits. However, this growth path faces market fragmentation, regulatory complexity, and substantial financial risk based on current balance sheet metrics.

Guardian Pharmacy Services, Inc. achieved $1.45 billion in revenue and $49.2 million in net income for the fiscal year ending December 31, 2025, reflecting a profitable trajectory supported by scale and operational efficiency. Despite moderate liquidity metrics—current ratio of 1.38—the company maintains financial stability amid working capital demands typical in pharmacy services. Capital allocation decisions emphasize shareholder returns via buybacks, while regulatory and disclosure risks underline the need for cautious monitoring of earnings visibility going forward.

Founded in 1995 as a Brazilian software R&D company, CI&T has transformed into a global technology transformation specialist with nearly 8,000 professionals worldwide. In 2025, the company posted an 11.5% revenue increase to $489.6 million, driven by strong organic growth, client expansion particularly within its top ten customers, and expanding AI-enabled offerings. Profitability rose sharply with net income up 37.7%, and adjusted EBITDA margins remained stable around 18%. CI&T's capital structure remains sound with prudent debt management and ongoing investments in proprietary technologies and talent. Looking forward, the firm anticipates sustained organic growth of approximately 14% in 2026 amid continued demand for integrated AI-driven digital transformations.

Acme United Corporation demonstrated steady revenue growth from fiscal year 2023 through 2025, reaching $196.5 million in revenue in FY2025 with improving operating income margins. The recent acquisition of My Medic in January 2026 marks a significant expansion into tactical and emergency response products, bringing new intellectual property and direct-to-consumer channels, albeit with integration risks. Operational cash flow remains robust despite a marked increase in capital expenditures linked to growth initiatives. The company maintains strong liquidity and has extended its revolving credit facility through mid-2027, supporting both acquisitions and working capital needs. Dividends have steadily increased while share repurchases are subdued, pointing to prudent cash allocation amid expansion.

Forward Air Corporation’s strategic acquisition of Omni Newco LLC in early 2024 transformed its revenue composition, with the Omni segment contributing about half of total revenues by 2025. Despite this diversification, the company’s top-line declined year-over-year by over 8%, and it reported a substantial net loss amid economic headwinds and integration costs. Forward Air’s asset-light model and technology-driven service differentiation remain competitive strengths, but freight volume sensitivity and tariff uncertainties pose risks to near-term stability. Capital discipline is evident through reduced capital expenditures and suspended dividends, while liquidity remains adequate but constrained by significant leverage.

Vista Gold Corp remains a pure development-stage gold company focused solely on its Mt Todd project, which registered significant technical progress with a 2024 feasibility study finalized. Despite no mining revenue, the company recorded a 2025 net loss of $7.5M driven by elevated exploration and feasibility expenses, yet sustains strong liquidity supported by a recent $44.85M equity raise. The pathway toward detailed engineering in 2027 depends heavily on securing permit modifications and managing execution risks amid volatile commodity markets and capital demands. While short-term cash flow trends show increased outflows tied to study expenditures, ongoing capital allocation emphasizes prudent balancing of dilution risk and project advancement.

LCNB CORP posted a significant 71.4% increase in net income for fiscal 2025, reaching $23.12 million despite subdued top-line revenue and a steep decline in operating cash flow. This earnings surge is closely tied to acquisition-related intangible asset accounting, including goodwill and core deposit intangibles subject to amortization and impairment tests. The company's disciplined approach to fair value measurements on debt securities and loans held-for-sale adds volatility but reflects a conservative risk posture. Capital allocation exhibits steady dividend payouts with a shift away from buybacks, supported by strong free cash flow generation and an approximate 8.4% return on equity. Emerging risks center on potential impairments of intangible assets and credit losses amid market fluctuations. Analysts should monitor intangible asset health metrics, loan sale trends, and cash flow consistency for insight into future earnings quality.

In Q1 2026, ACCO BRANDS Corp posted net sales of $343.7 million, up 8.3% year-over-year, primarily driven by pricing initiatives amid a slight decline in comparable sales. However, the company recorded an operating loss of $10.4 million, worsened by increased intangible amortization and higher selling expenses. With a diversified global product portfolio and extensive distribution channels, ACCO faces persistent risks from customer concentration, intense competition, and economic variability while continuing to invest in innovation and supply chain efficiency to support growth.

In Q1 2026, OraSure Technologies maintained strong liquidity while navigating ongoing net losses and regulatory complexities. The company’s business model encompasses proprietary diagnostic devices, integrated laboratory services including genomics, and comprehensive sample management solutions underpinned by FDA and international approvals. Its competitive moat is shaped by regulatory barriers, technological differentiation, and distributor networks, although regulatory delays and leadership transitions pose material risks. Looking ahead, product approvals and sales expansion will be critical milestones.

FIGX Capital Acquisition Corp., established as a Cayman Islands exempted blank check company in early 2025, completed its IPO mid-2025 raising approximately $150.65 million, which it holds in trust pending a business combination. The company focuses on acquiring differentiated private wealth and asset management firms with multi-asset capabilities and global reach, targeting companies with $10–50 billion in assets under management. Its experienced management team leverages deep industry connections to source proprietary deals and plans to add operational value post-acquisition. However, with no operating revenues or target selected as of the end of 2025, the company faces typical SPAC risks including timely deal execution and potential dilution.

Heritage Commerce Corp (HTBK), a San Jose-based regional bank, demonstrated resilient profitability in 2025 despite sector headwinds, growing operating cash flow significantly while net income dipped from prior peaks. The company’s strategic merger with CVB Financial Corp received regulatory approvals in early 2026, marking a key transitional milestone expected to enhance scale and operational efficiencies. Capital returns remained consistent with robust free cash flow funding dividends and buybacks. Post-merger execution risks center on integration challenges, regulatory compliance, and maintaining loan portfolio quality amid regional economic cycles.

Stellar V Capital Corp., a Cayman Islands-based SPAC formed in mid-2024, remains in its pre-business combination phase with no identified targets as of Q1 2026. The company raised $150 million in its January 2025 IPO, holding proceeds in trust while leveraging management's extensive deal-making experience to pursue acquisitions with durable competitive advantages. With a 21-month deadline to complete a business combination or face liquidation, the firm must accelerate execution amid challenging regulatory and market landscapes common in the SPAC sector. Financially, the company sustains operations through modest working capital, relying primarily on the IPO trust fund for future transactions.

In the first quarter of 2026, FreightCar America reported a contraction in its railcar backlog alongside a key acquisition aimed at bolstering its aftermarket distribution segment. The company's core business of designing and manufacturing specialized freight railcars remains anchored by patented products and long-standing customer relationships, though it faces cyclical demand patterns and supply chain risks. The newly acquired Carly Railcar Components will expand service offerings and parts supply capabilities, supporting growth beyond new railcar builds. The business operates in a competitive North American industry dominated by price sensitivity and delivery timing pressures, with concentrated buyers largely from financial institutions and shippers.

In its May 2026 quarterly filing, NET Power disclosed a significant operational update with the purchase contract for modular gas turbines to be deployed at Project Permian, marking a strategic shift from exclusive reliance on its proprietary oxy-combustion technology toward licensing post-combustion carbon capture (PCC) integration. This repositioning aligns with broader ambitions to expand market entry via licensing while updating the final investment decision (FID) timeline to H2 2026 and commercial operations targeted by early 2029. The company continues as a development-stage entity with no material revenue but maintains a robust liquidity buffer of approximately $133 million in cash and $318 million in total liquid assets at quarter-end. The key growth drivers revolve around successfully executing on Project Permian’s phased installation and scaling licensing arrangements, whereas risks center on regulatory shifts, capital intensity, supply-chain vulnerabilities, and intellectual property uncertainties.

In Q1 2026, Travelzoo reiterated its commitment to expanding its paid membership base and rolling out Metaverse travel experiences, key pillars in its evolving business model. The company continues to balance advertising, commerce, and membership revenues while navigating market volatility and execution risks. Geographically diversified operations with segments in North America, Europe, and newer initiatives underpin Travelzoo's growth strategy. However, recognition timing of membership fees and competitive pressures in digital travel media remain watchpoints. Capital allocation remains disciplined, including active share repurchases to optimize capital structure.

Zevra Therapeutics, Inc. delivered positive financial results in Q1 2026, underpinned by its lead orphan drug MIPLYFFA targeting Niemann-Pick Disease Type C. The company has streamlined its asset base through divestiture of the SDX portfolio to focus on core rare disease therapies, while appointing a new CFO to drive financial strategy. Operating within a challenging regulatory environment characterized by healthcare reforms in the U.S. and Europe, Zevra leverages orphan drug exclusivity to maintain pricing power and market niche leadership. Risks from evolving government reimbursement policies and cybersecurity remain key watchpoints as Zevra advances growth via commercialization expansion and regulatory compliance.

Korn Ferry posted a significant rebound in fiscal 2025 with 12.2% revenue growth and over 60% operating income increase, reflecting renewed consulting demand and operational leverage. The company strengthened its dividend policy amid rising net income and cash flow, demonstrating disciplined capital allocation. Despite risks inherent to cyclical professional services sectors, Korn Ferry’s strong liquidity and balance sheet provide strategic flexibility to navigate competitive pressures.

Peapack Gladstone Financial Corporation recorded a notable 24.1% revenue increase and a 31.6% rise in net income in 2025, underpinned by its relationship-driven private banking and wealth management expansion in the New Jersey and New York metro areas. Despite compressions in operating cash flow due to stepped-up investments, particularly in technology and branch development, the company maintains disciplined capital deployment balancing dividends, share buybacks, and capex. Challenges remain from evolving credit risks and regulatory costs, but the firm’s strong balance sheet and technological modernization efforts aim to sustain client service differentiation and financial resilience.

Target Hospitality Corp. reported mixed first-quarter 2026 performance with pressure from capital availability that could delay planned growth investments in its Workforce Hospitality Solutions segment. The company’s vertically integrated business model, combining modular lodging assets with comprehensive hospitality services, underpins stable recurring revenue from long-term contracts with blue-chip clients in natural resources, data centers, and government sectors. However, customer concentration and financing constraints remain key risks that could limit Target’s scalability and margin expansion. Monitoring new contract ramp-up, capital deployment progress, and liquidity developments will be critical for understanding the company’s near-term outlook.

Peoples Bancorp of North Carolina has demonstrated sustained earnings growth, propelled primarily by expansion in net interest income and loan portfolios concentrated in commercial and real estate sectors. Its community-centric business model creates a competitive moat through deep local ties and responsive management. Capital allocation remains disciplined with steady dividend payments and prudent buyback activity tapering in favor of reinvestment. Investors should monitor loan growth trends, credit quality signals, and evolving interest rate impacts in assessing future performance under shifting macroeconomic conditions.

In its latest 10-Q filing for Q1 2026, Broadwind, Inc. reported operational progress driven by consolidation of its heavy fabrications segment and sustained backlog around $96 million. The company's strategic reduction in reliance on U.S. wind energy, now representing 51% of sales versus 70% in 2020, underpins diversification efforts. Broadwind's manufacturing capabilities span heavy fabrications, gearing, and industrial solutions, supported by specialized processes and trade protections that grant a modest moat despite customer concentration risks. Key growth drivers include capacity optimization post-facility consolidation and expanding product mix outside wind towers. Notable risks persist around concentrated customer exposure and the challenge of adapting to rapid technological shifts in wind turbine components.

Mistras Group operates as a technology-enabled leader in asset protection across critical industries, delivering integrated non-destructive testing (NDT) and digital solutions fortified by its OneSuite™ IoT platform. Historical growth has been driven by technological enhancements and service diversification, with operating income rising modestly in FY2025 despite net income softness. The firm’s three-segment model—North America, International, and Products & Systems—provides broad industrial exposure and geographic reach. Capital allocation emphasizes reinvestment with a notable rise in capex supporting robotics and infrastructure upgrades, while balancing steady cash flow generation. Risks notably include tariff-related input cost pressures and intensifying technology competition, emphasizing the need for continued innovation to maintain its differentiated service offerings.

In the first quarter of 2026, Parke Bancorp reinforced its funding base by deepening core deposit relationships while supplementing liquidity through established brokered deposits and the IntraFi Financial Network. The company’s business model centers on serving small to mid-sized businesses and retail customers through focused lending in residential, commercial, and construction loans, supported by a stable retail deposit franchise. Its regional foothold in southern New Jersey and Philadelphia underpins a modest moat, but geographic concentration and interest rate fluctuations remain notable risks. Looking forward, monitoring deposit cost trends, loan growth momentum, and local economic conditions will be critical to assessing Parke Bancorp’s trajectory.

Inland Real Estate Income Trust, Inc. maintains a portfolio concentrated in grocery-anchored retail shopping centers that supports occupancy near 92% and a relatively stable annualized base rent profile. However, the company has incurred net losses for several consecutive years, reflecting operational costs amplified by its external management structure and constrained capital resources. Its capital structure features sizable revolving credit and term loan facilities with covenants that limit flexibility, while dividend payments and share repurchases continue despite these financial pressures. The board’s recent strategic review aims to enhance asset growth and liquidity, though no immediate milestones or liquidity events are guaranteed.

Photronics Inc. remains a pivotal player in semiconductor and flat panel display manufacturing by producing critical photomasks using advanced lithography across global facilities. Despite facing a 6% dip in operating income in FY2025, the company sustained net income growth supported by robust quality control and strategic R&D investments. Its customer concentration risk and geopolitical exposure represent ongoing challenges, yet Photronics’ increased capital expenditures and resumed buybacks signal confidence in long-term prospects. Key monitoring points include margin pressures and evolving semiconductor technology nodes where Photronics aims to maintain its technical leadership.

In the latest quarterly report ending September 2025, MYOMO demonstrated operational traction by surpassing revenue expectations even though net losses persisted. The company appointed William J. Febbo to its board in April 2026, bolstering strategic oversight with extensive medical device industry expertise. MYOMO’s business model centers on specialized mobility-enhancement devices with proprietary technology, maintaining competitive differentiation amid regulatory and market challenges. Financing through a $17.5 million committed term loan supports near-term development and commercialization initiatives but brings covenant constraints. Key risks remain around sustained losses and the pressure of ongoing innovation in a regulated environment.

Katapult Holdings, Inc. operates a technology-driven lease-to-own platform targeting underserved nonprime U.S. consumers through omnichannel retail partnerships and proprietary underwriting technology. In its latest quarterly filing for Q1 2026, Katapult highlighted continued growth in gross originations enabled by expanding merchant integrations and its KPay platform, while simultaneously navigating substantial indebtedness with ongoing waivers of financial covenants as it prepares for a pending transformational merger with CCFI and Aaron's. The company’s model leverages flexible lease-purchase agreements with no long-term obligation, uniquely serving a large nonprime population underserved by traditional credit. Risks include execution uncertainty around the proposed mergers, dependence on key merchant relationships, substantial debt and covenant compliance pressures, and regulatory complexities inherent in its highly regulated industry segment.

After suffering steep net losses in 2023 and 2024, Tredegar Corporation posted a net income of $33.5 million in 2025, demonstrating a significant financial recovery. This turnaround was supported by increased sales volume, improved operating cash flow, and effective management of commodity cost pass-throughs in its Aluminum Extrusions and High Performance Films segments. The company maintained compliance with debt covenants while suspending dividends and share buybacks to prioritize liquidity and reinvestment. Key near-term indicators for performance focus on segment EBITDA trends and metal price volatility.

Rocky Brands delivered a notable turnaround in FY2025 with double-digit revenue growth and nearly doubled net income, driven by growth across Wholesale, Retail, and Contract Manufacturing segments. The company's multi-channel emphasis—especially surging Retail sales supported by e-commerce and B2B platforms—coupled with tariff mitigation strategies through expanded company-owned manufacturing, underpinned margin improvements despite cost headwinds. While cash flow generation softened considerably due to inventory build and tariff-related costs, disciplined capital allocation sustained dividend payouts with modest buybacks. Key monitoring areas include the effectiveness of ongoing tariff adjustments, retail channel profitability, and product innovation trajectories.

Campbell's Co has demonstrated steady revenue growth driven by its core branded products over recent years. However, the company faces persistent margin pressures from commodity inflation, tariffs, and volume softness across its key segments. Strategic cost savings initiatives targeting $375 million in annual run-rate savings by 2028 aim to mitigate these challenges. Capital allocation remains focused on consistent dividends and active share repurchase programs while managing near-term debt maturities with a solid liquidity position. The recent acquisition of a minority stake in La Regina, producer of Rao’s pasta sauces, positions Campbell's for potential premium segment growth amid an uncertain macroeconomic environment.

GPO Plus, Inc. (GPOX) has evolved from its origins into a technology-centric Direct Store Delivery (DSD) distributor focusing on underserved convenience store segments in the Midwest. Leveraging its proprietary PRISM+ platform and a network of Regional and Mini Hubs, GPOX targets the fragmented 15%-20% market share not served by broadline distributors by offering weekly DSD services combined with proprietary product manufacturing. Despite solid revenue growth near 9% year-over-year through FY2025, the company continues to operate at a loss due to scaling investments and liquidity constraints. Operational efficiencies driven by vertical integration and data analytics underpin its moat, but execution risks tied to cash flow remain pivotal as GPOX plans expansion beyond its core geography.

Uranium Energy Corp (UEC) has built its growth around low-cost in-situ recovery uranium mining primarily in the U.S. and Canada, complemented by a strategic Physical Uranium Program that bolsters liquidity and marketing flexibility. Operational revenues emerged notably since FY2023 driven by Christensen Ranch ramp-up, though operating losses have deepened reflecting ongoing development investments. The launch of United States Uranium Refining & Conversion Corp (UR&C) marks vertical integration into refining and conversion, enhancing supply chain control and positioning UEC to benefit from increasing U.S. government incentives promoting domestic nuclear fuel production. Liquidity remains ample via multiple equity raises underpinning capex for exploration and project development with a focus on scaling production and securing origin premium sales in a structurally tight global uranium market.

SuRo Capital Corp., a business development company specializing in private equity investments in innovative sectors, filed its latest 10-Q on May 6, 2026, highlighting no material changes in risk factors but emphasizing an ongoing transition towards an external management model. The company announced a joint venture with Magnetar Holdings to outsource its investment advisory services, aiming to leverage Magnetar's multi-strategy platform. SuRo maintains a diversified portfolio with a significant portion in Level 3 Fair Value investments, and continues to face risks related to RIC compliance, leverage, and regulatory changes. Growth depends heavily on sourcing high-growth private investments and managing leverage within regulatory constraints.

Athena Technology Acquisition Corp. II, a special purpose acquisition company (SPAC) focused on fintech and technology sectors, is nearing a critical deadline to consummate its initial business combination with Ace Green Recycling amid a protracted extension saga and financial pressures. Having been delisted from the NYSE American due to delays, Athena currently operates as a shell company with limited liquidity and mounting working capital deficits. The successful completion of the merger could transform Athena into an operating public entity with growth prospects rooted in inorganic expansion and operational leverage post-acquisition. However, execution risks remain high given weak balance-sheet metrics and ongoing regulatory compliance challenges.

Sagimet Biosciences Inc. reported a solid liquidity position with over $100 million in cash, enabling continued clinical development of its lead FASN inhibitor, denifanstat, for metabolic dysfunction-associated steatohepatitis (MASH) and acne. The recent quarter highlighted sustained R&D focus with no revenues, typical for a clinical-stage biopharma. Sagimet’s differentiation lies in its selective oral FASN inhibitors and strategic partnership in Greater China. Key growth drivers include late-stage clinical data and potential combination therapies targeting advanced fibrosis. Risks center on inherent clinical trial uncertainties and the need for ongoing capital to sustain operations.